Sex
|
Male
|
59
|
56.7
|
50
|
59.5
|
3
|
60
|
3
|
50
|
0
| |
1
|
50
|
2
|
28.6
|
Female
|
45
|
43.2
|
34
|
40.5
|
21
|
40
|
32
|
50
|
22
|
100
|
1
|
50
|
51
|
71.4
|
Age (years)
| | | | | | | |
Mean
|
18.1
|
17.5
|
17.8
|
29
|
19
|
18.5
|
15.7
|
Range
|
2–53
|
2–53
|
12–26
|
12–45
|
12–24
|
15–22
|
9–26
|
Tumor size
|
Mean (cm)
|
8.8
| | | | | | |
< 9 cm
|
51
|
49
|
38
|
45.2
|
41
|
80
|
22
|
33.3
|
22
|
100
|
2
|
100
|
51
|
71.4
|
> 9 cm
|
43
|
41.3
|
38
|
45.2
|
1
|
20
|
3
|
50
|
0
| |
0
| |
1
|
14.3
|
Unknown
|
10
|
9.6
|
8
|
9.5
|
0
| |
1
|
16.6
|
0
| |
0
| |
1
|
14.3
|
Tumor volume
| | | | | | | | | | | | | | |
< 200 ml
|
18
|
17.3
| | | | | | | | | | | | |
> 200 ml
|
35
|
33.6
| | | | | | | | | | | | |
Unknown
|
51
|
49
| | | | | | | | | | | | |
Tumor location
| | | | | | | |
Upper posterior
|
52
|
50
|
43
|
51.2
|
51
|
100
|
2
|
33.3
|
0
| |
0
| |
31
|
42.9
|
Lower anterior
|
31
|
29.8
|
25
|
29.8
|
0
| |
22
|
33.3
|
12
|
50
|
0
| |
4
|
57.1
|
Periacetabular
|
18
|
17.3
|
15
|
17.8
|
0
| |
2
|
33.3
|
1
|
50
|
0
| |
0
| |
Gluteal
|
2
|
1.9
|
0
| |
0
| |
0
| |
0
| |
2
|
100
|
0
| |
Unknown
|
1
|
0.9
|
1
|
1.2
|
0
| |
0
| |
0
| |
0
| |
0
| |
Surgical procedure
|
Internal intraarticular
|
51
|
49
|
43
|
51.2
|
0
| |
22
|
33.3
|
12
|
50
|
1
|
50
|
5
|
71.4
|
Internal extraarticular
|
13
|
12.5
|
9
|
10.7
|
0
| |
2
|
33.3
|
1
|
50
|
1
|
50
|
0
| |
Internal (without joint involvement)
|
39
|
37.5
|
31
|
36.9
|
51
|
100
|
2
|
33.3
|
0
| |
0
| |
21
|
28.6
|
Hindquarter amputation
|
1
|
0.9
|
1
|
1.2
|
0
| |
0
| |
0
| |
0
| |
0
| |
Resection type (Enneking)
| | | | | | | |
P1a
|
3
|
2.9
|
0
| |
31
|
60
|
0
| |
0
| |
0
| |
11
|
14.3
|
P1b
|
1
|
0.9
|
0
| |
1
|
20
|
0
| |
0
| |
0
| |
0
| |
P1-2
|
2
|
1.9
|
2
|
2.4
|
0
| |
0
| |
0
| |
0
| |
0
| |
P1c
|
31
|
29.8
|
27
|
32.1
|
1
|
20
|
2
|
33.3
|
0
| |
0
| |
1
|
14.3
|
P1c + HS
|
2
|
1.9
|
2
|
2.4
|
0
| |
0
| |
0
| |
0
| |
0
| |
P1-2-3
|
2
|
1.9
|
2
|
2.4
|
0
| |
0
| |
0
| |
0
| |
0
| |
P1-2-4
|
14
|
13.5
|
11
|
13.1
|
0
| |
0
| |
0
| |
2
|
100
|
1
|
14.3
|
P1-2-4 + HS
|
2
|
1.9
|
2
|
2.4
|
0
| |
0
| |
0
| |
0
| |
0
| |
P1-2-3-4
|
15
|
14.4
|
12
|
14.3
|
0
| |
2
|
33.3
|
1
|
50
|
0
| |
0
| |
P1-2-3-4 + HS
|
1
|
0.9
|
1
|
1.2
|
0
| |
0
| |
0
| |
0
| |
0
| |
P2
|
1
|
0.9
|
0
| |
0
| |
0
| |
0
| |
0
| |
1
|
14.3
|
P2-3
|
14
|
13.5
|
12
|
14.3
|
0
| |
12
|
16.6
|
12
|
50
|
0
| |
1
|
14.3
|
P3
|
15
|
14.4
|
12
|
14.3
|
0
| |
1
|
16.6
|
0
| |
0
| |
2
|
28.6
|
Unknown
|
1
|
0.9
|
1
|
1.2
|
0
| |
0
| |
0
| |
0
| |
0
| |
Reconstruction types
| | | | | | | |
Hip transposition
|
33
|
31.7
| | | | | | | | | | | | |
Hip transposition w/proximal femur replacement
|
9
|
8.7
| | | | | | | | | | | | |
Hip transposition spacer
|
2
|
1.9
| | | | | | | | | | | | |
Pelvic implant
|
1
|
0.9
|
Combined with hip transposition, n = 1
|
Flail hip
|
1
|
0.9
|
Combined with hip transposition, n = 1
|
Screw-rod reconstruction w/bone cement sheath
|
19
|
18.3
| | | | | | | | | | | | |
Autologous iliac bone graft osteosynthesis
|
6
|
5.8
|
Combined with hip transposition, n = 1
|
Autologous fibula bone graft osteosynthesis
|
5
|
4.8
|
Combined with hip transposition, n = 1
|
Allograft osteosynthesis
|
7
|
6.7
| | | | | | | | | | | | |
Soft tissue reconstruction only
|
21
|
20.2
| | | | | | | | | | | | |
EWSR 1 translocation status
|
Present
|
62
|
59.6
| | | | | | |
Absent
|
2
|
1.9
| | | | | | |
Unknown
|
40
|
38.5
| | | | | | |
Histologic response to neoadjuvant chemotherapy (Salzer-Kuntschik)
| | | | | | | |
1 (no vital tumor)
|
54
|
51.9
|
46
|
54.8
|
51
|
100
|
1
|
16.6
|
0
| |
0
| |
31
|
42.9
|
2 (isolated cells)
|
6
|
5.8
|
3
|
3.6
|
0
| |
1
|
16.6
|
0
| |
0
| |
2
|
28.6
|
3 (< 10% viable cells)
|
22
|
21.2
|
18
|
21.4
|
0
| |
0
| |
0
| |
2
|
100
|
2
|
28.6
|
4 (10–50% viable cells)
|
13
|
12.5
|
11
|
13.1
|
0
| |
22
|
33.3
|
12
|
50
|
0
| |
0
| |
5 (> 50% viable cells)
|
5
|
4.8
|
3
|
3.6
|
0
| |
2
|
33.3
|
0
| |
0
| |
0
| |
6 (no response to chemo)
|
1
|
0.9
|
0
| |
0
| |
0
| |
1
|
50
|
0
| |
0
| |
Unknown
|
3
|
2.9
|
3
|
3.6
|
0
| |
0
| |
0
| |
0
| |
0
| |
Surgical margins
| | | | | | | | | | | | | | |
R0
|
98
|
94.2
|
78
|
92.8
|
51
|
100
|
62
|
100
|
22
|
100
|
2
|
100
|
71
|
100
|
Planned R1
|
2
|
1.9
|
2
|
2.4
|
0
| |
0
| |
0
| |
0
| |
0
| |
Unplanned R1
|
2
|
1.9
|
2
|
2.4
|
0
| |
0
| |
0
| |
0
| |
0
| |
Unknown
|
2
|
1.9
|
2
|
2.4
|
0
| |
0
| |
0
| |
0
| |
0
| |
Disease extent
|
Localized
|
34
|
32.7
|
34
|
40.5
|
0
| |
0
| |
0
| |
0
| |
0
| |
Metastatic at diagnosis
|
45
|
43.3
|
30
|
35.7
|
51,3
|
100
|
62
|
100
|
22
|
100
|
2
|
100
|
21
|
28.6
|
Metastatic after pelvic resection
|
17
|
16.3
|
17
|
20.2
|
0
| |
0
| |
0
| |
0
| |
0
| |
Unknown
|
8
|
7.7
|
3
|
3.6
|
0
| |
0
| |
0
| |
0
| |
5
|
71.4
|
Number of metastatic organ sites
| | | | | | | |
Single (one other organ system)
| | |
22
| | | | | | | | | | | |
Multiple (> 1 other organ systems)
| | |
7
| | | | | | | | | | | |
Local recurrence
| | | | | | | | | | | | | | |
|
8
|
7.7
|
6
|
7.1
|
0
| |
2
|
33.3
|
0
| |
0
| |
0
| |
Radiation
|
Yes
|
81
|
77.8
| | | | | | | | | | | | |
Neoadjuvant
|
17
|
16.3
|
14
|
16.6
|
0
| |
22,4
|
33.3
|
22
|
100
|
0
| |
0
| |
Adjuvant
|
53
|
51
|
46
|
54.8
|
3
|
60
|
1
|
16.6
|
0
| |
1
|
50
|
2
|
28.6
|
Other
|
11
|
10.6
|
9
|
10.7
|
0
| |
0
| |
0
| |
1
|
50
|
1
|
14.3
|
No
|
17
|
16.3
|
12
|
14.3
|
21
|
40
|
3
|
50
|
0
| |
0
| |
11
|
14.3
|
Unknown
|
6
|
5.8
|
3
|
3.6
|
0
| |
0
| |
0
| |
0
| |
3
|
42.9
|